HK1223302A1 - 具有 的凝血酶可裂解連接子和其用途 - Google Patents

具有 的凝血酶可裂解連接子和其用途

Info

Publication number
HK1223302A1
HK1223302A1 HK16111718.0A HK16111718A HK1223302A1 HK 1223302 A1 HK1223302 A1 HK 1223302A1 HK 16111718 A HK16111718 A HK 16111718A HK 1223302 A1 HK1223302 A1 HK 1223302A1
Authority
HK
Hong Kong
Prior art keywords
xten
cleavable linker
thrombin cleavable
thrombin
linker
Prior art date
Application number
HK16111718.0A
Other languages
English (en)
Inventor
Ekta Seth Chhabra
John Kulman
Tongyao Liu
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of HK1223302A1 publication Critical patent/HK1223302A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
HK16111718.0A 2013-06-28 2016-10-11 具有 的凝血酶可裂解連接子和其用途 HK1223302A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840872P 2013-06-28 2013-06-28
PCT/US2014/044731 WO2014210558A1 (en) 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof

Publications (1)

Publication Number Publication Date
HK1223302A1 true HK1223302A1 (zh) 2017-07-28

Family

ID=52142742

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111718.0A HK1223302A1 (zh) 2013-06-28 2016-10-11 具有 的凝血酶可裂解連接子和其用途

Country Status (17)

Country Link
US (3) US20160251408A1 (zh)
EP (2) EP4368194A2 (zh)
JP (5) JP2016523919A (zh)
KR (3) KR20240023705A (zh)
CN (3) CN113831415A (zh)
AU (3) AU2014302100B2 (zh)
CA (1) CA2913078A1 (zh)
CL (1) CL2015003710A1 (zh)
EA (1) EA201592022A1 (zh)
HK (1) HK1223302A1 (zh)
IL (3) IL297611A (zh)
MX (1) MX2015016567A (zh)
NZ (1) NZ713904A (zh)
PH (1) PH12015502614A1 (zh)
SG (3) SG11201509313PA (zh)
TW (3) TW202313672A (zh)
WO (1) WO2014210558A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
NZ626945A (en) 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
KR20190094480A (ko) 2012-02-15 2019-08-13 바이오버라티브 테라퓨틱스 인크. 재조합 인자 viii 단백질
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
PT2882450T (pt) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SI3091997T1 (sl) * 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc. Himerni proteini faktorja VIII in njihova uporaba
KR20170125942A (ko) * 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 폰 빌레브란트 인자의 반감기 개선용 화합물
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
JP6877469B2 (ja) * 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
KR20190085021A (ko) * 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
JP2003526625A (ja) * 1999-07-23 2003-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血小板の活性化の調節
WO2004076484A1 (en) * 2003-02-27 2004-09-10 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
LT2068907T (lt) * 2006-10-04 2018-01-10 Novo Nordisk A/S Glicerolio sujungti pegilinti sacharidai ir glikopeptidai
AU2008323768A1 (en) * 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
ES2654336T3 (es) * 2008-06-24 2018-02-13 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
EP2368124A4 (en) * 2008-11-24 2012-09-19 Bayer Healthcare Llc METHOD FOR DETERMINING THE ACTIVITY OF A PEGYLATED BLOOD GENERATION FACTOR IN A SILICON-BASED ACTIVATED PART THROMBOPLASTINE TIME ASSAY
CN102348715B (zh) * 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8716448B2 (en) * 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
JP5544219B2 (ja) * 2009-09-24 2014-07-09 富士フイルム株式会社 内視鏡システム
US8759293B2 (en) * 2009-11-13 2014-06-24 Grifols Therapeutics Inc. von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
WO2011069164A2 (en) * 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US20110312881A1 (en) * 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EP3508573A1 (en) * 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
NZ626945A (en) * 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
CN111548418A (zh) * 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
PT2882450T (pt) * 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
US20160229903A1 (en) * 2013-06-28 2016-08-11 Biogen Ma Inc. Thrombin cleavable linker
SI3091997T1 (sl) * 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc. Himerni proteini faktorja VIII in njihova uporaba

Also Published As

Publication number Publication date
US20220106383A1 (en) 2022-04-07
BR112015031194A2 (pt) 2017-09-19
NZ713904A (en) 2022-02-25
SG10201913738YA (en) 2020-03-30
JP2019010124A (ja) 2019-01-24
EP4368194A2 (en) 2024-05-15
PH12015502614A1 (en) 2016-02-29
IL297611A (en) 2022-12-01
TW201514204A (zh) 2015-04-16
AU2023219840A1 (en) 2023-09-14
EP3013358A4 (en) 2017-03-22
JP2016523919A (ja) 2016-08-12
AU2014302100A1 (en) 2015-11-26
CA2913078A1 (en) 2014-12-31
IL266462B (en) 2022-12-01
SG11201509313PA (en) 2016-01-28
US20240083975A1 (en) 2024-03-14
CN105392495A (zh) 2016-03-09
US20160251408A1 (en) 2016-09-01
KR20230007555A (ko) 2023-01-12
TW202045535A (zh) 2020-12-16
WO2014210558A1 (en) 2014-12-31
IL266462A (en) 2019-06-30
EP3013358A1 (en) 2016-05-04
CL2015003710A1 (es) 2016-08-26
AU2020203063A1 (en) 2020-05-28
SG10201710616XA (en) 2018-02-27
JP2021072853A (ja) 2021-05-13
KR20240023705A (ko) 2024-02-22
KR20160023654A (ko) 2016-03-03
IL242436B (en) 2019-05-30
TW202313672A (zh) 2023-04-01
EA201592022A1 (ru) 2016-05-31
JP7297837B2 (ja) 2023-06-26
JP7005800B2 (ja) 2022-02-10
AU2020203063B2 (en) 2023-05-25
IL266462B2 (en) 2023-04-01
AU2014302100B2 (en) 2020-02-13
MX2015016567A (es) 2016-03-31
TWI770467B (zh) 2022-07-11
CN113817069A (zh) 2021-12-21
CN113831415A (zh) 2021-12-24
JP2023107932A (ja) 2023-08-03
JP2022000053A (ja) 2022-01-04
TWI716340B (zh) 2021-01-21

Similar Documents

Publication Publication Date Title
IL266462B (en) Binding of thrombin that degrades with castane and uses thereof
IL291329A (en) Polypeptides that can be determined in matrix metalloproteinases and uses thereof
HK1220679A1 (zh) 基於植物的組合物及其應用
LT2958944T (lt) Antikūno prieš dll3 ir pbd konjugatai bei jų panaudojimas
EP3013347A4 (en) Glycan conjugates and use thereof
HK1223303A1 (zh) 凝血酶可裂解連接子
EP2968561A4 (en) Biophotonic materials and uses thereof
PT2877490T (pt) Inteínas clivadas, conjugados e suas utilizações
EP2968339A4 (en) Mk2 inhibitors and uses thereof
EP2885318A4 (en) PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF
EP2983681A4 (en) Therapeutic compositions and uses thereof
EP3010990A4 (en) Adhesive compositions and use thereof
GB201321693D0 (en) Composition and uses thereof
EP3068443A4 (en) Residualizing linkers and uses thereof
EP2992334A4 (en) Novel phosphatidylalkanols and compositions thereof
EP2953978A4 (en) PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF
EP3039131A4 (en) Enzyme composition and uses thereof
TWI562776B (en) Pharmaceutical composition and uses thereof
GB201309178D0 (en) Enzyme and uses thereof
EP2953627A4 (en) NSAIDs DERIVATIVES AND USES THEREOF
EP3083520A4 (en) Novel nanodisc clathrates and uses thereof
EP3019165A4 (en) Dehydroleucodine derivatives and uses thereof
GB201301022D0 (en) Composition and uses thereof
AU2013903558A0 (en) Improvements in rock bolts
AU2013903143A0 (en) Improvements in rock bolts